Results 171 to 180 of about 4,627,885 (297)

Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway

FEBS Open Bio, EarlyView.
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo, Sandy Richter, Christoph Bach, Wieland Kiess, Anna Kirstein, Diana Le Duc, Antje Garten   +6 more
wiley   +1 more source

Novel Protein Kinase Inhibitors: SMART Drug Design Technology

BioTechniques, 2003
Tomi K. Sawyer, Regine S. Bohacek, Chester A. Metcalf III, William C. Shakespeare, Yihan Wang, Raji Sundaramoorthi, Terence Keenan, Surinder Narula, Manfred Weigele, David C. Dalgarno   +9 more
doaj   +1 more source

Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods. [PDF]

Clin Pharmacokinet
Le Louedec F, Morvan L, Mourey L, Maillard M, Vachoux C, Yakoubi M, Tosi D, Gravis G, Roubaud G, Thuillier F, Boyle H, Thomas F, White-Koning M, Puisset F, Chatelut É.   +14 more
europepmc   +1 more source

Revisiting the inhibitory potential of protein kinase inhibitors against NEK7 protein via comprehensive computational investigations. [PDF]

Sci Rep, 2023
Ejaz SA, Aziz M, Zafar Z, Akhtar N, Ogaly HA.   +4 more
europepmc   +1 more source

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications. [PDF]

Research (Wash D C)
Baldi S, Long N, Ma S, Liu L, Al-Danakh A, Yang Q, Deng X, Xie J, Tang H.   +8 more
europepmc   +1 more source

Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD. [PDF]

Front Pharmacol, 2022
Yu H, Su X, Lei T, Zhang L, Feng Z, Zhang C, Zhang M, Wang Y, Chen X, Liu J.   +9 more
europepmc   +1 more source

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

Views of European Union medicine regulators and healthcare professionals on the approved versus prescribed dose of protein kinase inhibitors: an interview study. [PDF]

BMJ Open
Brinkhof M, de Vries ST, Mol PGM, Trapani D, Marije de Jong I, Broekman KE.   +5 more
europepmc   +1 more source

Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency. [PDF]

Pharmacol Res Perspect, 2023
Maliepaard M, Faber YS, van Bussel MTJ.
europepmc   +1 more source